Faron Pharmaceuticals Oy, a clinical-stage biopharmaceutical company focused on novel immunotherapies for cancer treatment, has received notifications from option holders to exercise options over shares in the company. The exercise of options includes 2015B, 2015D, and 2019 C bis options, resulting in the issue of new ordinary shares. The new shares are expected to be admitted to trading on AIM and Nasdaq First North Growth Market, with the enlarged issued number of shares reaching 68,807,199 ordinary shares with voting rights attached.

The BEXMAB study, an open-label Phase 1/2 clinical trial, is investigating bexmarilimab in combination with standard of care in aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Bexmarilimab, Faron's investigational immunotherapy, targets Clever-1, an immunosuppressive receptor found on macrophages, to overcome resistance to existing treatments and optimize clinical outcomes. It aims to reprogram macrophages from an immunosuppressive state to an immunostimulatory one, priming the immune system to attack tumors and sensitizing cancer cells to standard care.

Faron Pharmaceuticals Ltd. is a global, clinical-stage biopharmaceutical company focused on novel immunotherapies for cancer treatment. Its lead asset, bexmarilimab, is a novel anti-Clever-1 humanized antibody being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

The company has provided contact information for investor and media inquiries, as well as details about the BEXMAB study and bexmarilimab. The announcement also includes forward-looking statements, highlighting the company's mission to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system.

For more information, interested parties can visit the company's website at www.faron.com.